The Company added five assets to its industry-leading biosimilars pipeline, which now comprises 28 molecules. Pembrolizumab and nivolumab, two oncology assets addressing more than USD 40 billion ...

Checkpoint inhibitors like nivolumab and relatlimab act by removing ... is one of the drugs intended to step into its shoes after biosimilar competition starts – the failed trial comes as ...

The US FDA also recently highlighted the lack of activity of pembrolizumab, nivolumab ... driven by lower headcount and lower cost due to biosimilar divestitures in the first half of 2024.

It's worth noting also that Yervoy is not too far away from patent expiry, so Opdualag will help bolster BMS' cancer immunotherapy franchise once biosimilar rivals reach the market. BMS has high ...

4 The CHMP also recommended new indications for nivolumab (Opdivo) and ipilimumab (Yervoy), both reference products with several biosimilars in development. Should they be approved, the new indication ...

Highlights include the acceptance of a biologics license application for HLX11, a pertuzumab (Perjeta) biosimilar for HER2-positive breast ... biologics license application for the combination of ...

The Oxaliplatin, Fluorouracil, and Leucovorin (OFL) + sorafenib group and the sintilimab + bevacizumab biosimilar group decreased the risk ... the AEs network plots showed that more research compared ...

Neoadjuvant nivolumab has demonstrated efficacy in patients with mismatch repair-deficient, surgically resectable endometrial cancer.